all report title image
  • Published On : Jan 2022
  • Code : CMI4889
  • Industry : Biotechnology
  • Pages : 140
  • Formats :

Gene therapy can be described as the transfer of genetic material mostly in a vector or carrier while cell therapy includes the transfer of cells with the applicable function into the patient’s body. In the broader sense, gene therapy involves introduction, withdrawal, or modification in genetic code with an aim of curing or treating a disease. Gene therapy can be utilized to minimize the level of a disease-causing form of a protein and enhance the production of disease-fighting proteins, or to produce modified proteins. Cell therapy is the transfer of live, intact cells into a patient’s body in order to cure or treat a disease. The introduced cells can be from patient’s own body or from the donor. The cells utilized in cell therapy can be categorized by their possibilities to transform into different cell types. Cell and gene therapies are widely used to treat severe diseases such as cancer as well as rare diseases such as sickle cell disease, muscular dystrophy, and progeria.

The U.K. cell and gene therapy research challenges market is estimated to be valued at US$ 848 million in 2021 and is expected to exhibit a CAGR of 23.6% over the forecast period (2021-2028).

Figure 1. U.K. Cell and Gene Therapy Research Challenges Market Share (%), By Therapy Type, 2021

U.K. Cell and Gene Therapy  | Coherent Market Insights

The increasing product launches and approvals are expected to drive the market growth over the forecast period.

For instance, in October 2018, Bluebird bio, Inc. a biotechnology company, received European Medicines Agency (EMA) acceptance for the company’s authorization application (MAA) for its investigational ‘LentiGlobin gene therapy’. This therapy is used for treating adults and adolescents suffering from transfusion-dependent β-thalassemia (TDT). LentiGlobin gene therapy being studied as a possible treatment to address the significant genetic cause of TDT which may reduce or eliminate the requirement for blood transfusions.

CMI table icon

U.K. Cell and Gene Therapy Research Challenges Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 848 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 23.6% 2028 Value Projection: US$ 2525 Mn
Geographies covered:
  • U.K.
Segments covered:
  • By Therapy Type: Cell Therapy (Stem Cells, T Cells, Dendritic Cells, NK Cells), Gene Therapy (Germline Gene Therapy, Somatic Gene Therapy)
  • By Indication: Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, Others
Companies covered:

Novartis International AG, Pfizer Inc., Sanofi S.A., Amgen, Inc., PTC Therapeutics, Inc., Orchard Therapeutics Plc., Biomarin Pharmaceutical Inc., Regeneron, Bluebird Bio, Inc. (Celgene Corporation),  Freeline Therapeutics Ltd,  MeiraGTx Limited, Kolon TissueGene, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Biogen INC, and Bristol-Myers Squibb Company

Growth Drivers:
  • Increasing approval and launch of novel gene therapies for treatment of various rare diseases
  • Robust pipeline of products
  • Rising research and development activities for the development of novel technology
Restraints & Challenges:
  • Unfavorable reimbursement policies
  • Manufacturing issues limiting the availability of products at treatment centers 

Figure 2. U.K. Cell and Gene Therapy Research Challenges Market Share (%), By Indication, 2021

U.K. Cell and Gene Therapy  | Coherent Market Insights

The increasing adoption of inorganic growth strategies such as mergers, collaborations, partnerships, and acquisitions by key players in order to strengthen their position in the U.K. market is expected to drive the market growth over the forecast period.

For instance, in March 2019, Biogen Inc., pioneers in neuroscience entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company, to set up a clinical pipeline of gene therapy candidates in the field of ophthalmology.

U.K. Cell and Gene Therapy Research Challenges Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic has made significant impact on the UK cell and gene therapy market.

The cell and gene therapy development activities had slowed down in pandemic as companies had switched focus to vaccine production. The regulatory guidelines for advanced therapy medicinal products (ATMPs) is complex, with complexities in reimbursement environment, regulatory regime, and supply chain.  There are issues in conduction of trials for small patient population suffering through rare diseases. These complications have increased due to COVID-19 pandemic.

U.K. Cell and Gene Therapy Research Challenges Market - Restraint

Unfavourable reimbursement policies and manufacturing issues limiting the availability of products at treatment centres are expected to hinder growth of the U.K. cell and gene therapy research challenges market over the forecast period. However, cell and gene therapy has witnessed multiple setbacks from regulatory authorities in charge of reimbursement policy, which is expected to inhibit growth of the market.

For instance, in August 2018, the National Institute for Health and Care Excellence (NICE), U.K. concluded that Yescarta is a very expensive therapy and hence cannot be considered as a cost-effective use of National Health System (NHS) resources.

Key Players

Major players operating in the U.K. cell and gene therapy research challenges market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., PTC Therapeutics, Inc., Orchard Therapeutics Plc., Biomarin Pharmaceutical Inc., Regeneron, Bluebird Bio, Inc. (Celgene Corporation), Freeline Therapeutics Ltd,  MeiraGTx Limited, Kolon TissueGene, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Biogen INC., and  Bristol-Myers Squibb Company.

Cell therapy can be defined as the transfer of new cells into a patient’s body to repair or replace damaged tissue or cells to treat a disease. The introduced cells can be from patient’s own body or from the donor. Different types of cells can be utilized in cell therapy such as lymphocytes, pancreatic islet cells, stem cells, and dendritic cells. This technology of cell therapy enables the development of various types of specific human cells required for therapeutic purposes. While gene therapy involves introduction or modification of genes into a patient’s body with an objective of providing treatment, prevention or to cure a disease.

The gene therapy alters a person’s genes to cure or treat disease. This process involves various mechanisms such as introduction of modified or new gene into the patient’s body in order to treat a disease, replacement of a disease causative gene by a healthy gene copy, or inactivation of a disease causing gene which exhibits improper functioning. Gene and cell therapies may provide long lasting impact than traditional medicines.

Market Dynamics

Rising research and development activities for the development of novel technology, increasing approvals and launches of novel gene therapies for treatment of various rare diseases and robust pipeline of products which are expected to gain approval over the forecast period. Additionally, increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the U.K. cell and gene therapy research challenges market over the forecast period.

For instance, in August 2018, Novartis International AG, a global healthcare company, received European Commission’s (EC) approval for ‘Kymriah’. It is approved for the indication of treatment of patients up to 25 years of age with refractory or relapse B-cell acute lymphoblastic leukemia and for treating adult patients with refractory or relapsed diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Key features of the study:

  • This report provides in-depth analysis of the U.K. cell and gene therapy research challenges market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.K. cell and gene therapy research challenges market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., PTC Therapeutics, Inc., Orchard Therapeutics Plc., Biomarin Pharmaceutical Inc., Regeneron, Bluebird Bio, Inc. (Celgene Corporation), Freeline Therapeutics Ltd, MeiraGTx Limited, Kolon TissueGene, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Biogen Inc., and Bristol-Myers Squibb Company 
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.K. cell and gene therapy research challenges market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.K. cell and gene therapy research challenges market

Detailed Segmentation:

  • U.K. Cell and Gene Therapy Research Challenges Market, By Therapy Type:
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
    • Gene Therapy
      • Germline Gene Therapy
      • Somatic Gene Therapy
  • U.K. Cell and Gene Therapy Research Challenges Market, By Indication :
    • Dermatology
    • Musculoskeletal
    • Oncology
    • Immunology
    • Cardiology & Neurology 
    • Others
  • Company Profiles
    • Novartis International AG*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Sanofi S.A.
    • Amgen, Inc.
    • PTC Therapeutics, Inc.
    • Orchard Therapeutics Plc.
    • Biomarin Pharmaceutical Inc.
    • Regeneron
    • Bluebird Bio, Inc. (Celgene Corporation)
    • Freeline Therapeutics Ltd
    • MeiraGTx Limited
    • Kolon TissueGene, Inc.
    • Kite Pharma, Inc. (Gilead Sciences, Inc.)
    • Biogen INC
    • Bristol-Myers Squibb Company

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The U.K. cell and gene therapy research challenges market size is estimated to be valued at US$ 848 million in 2021 and is expected to exhibit a CAGR of 23.6% between 2021 and 2028.
Increasing approvals and launches of novel gene therapies for treatment of various rare diseases, rising research and development activities for the development of novel technology, and robust pipeline of products which are expected to gain approval over the forecast period are expected to drive the market growth over the forecast period.
Cell therapy segment is expected to hold major market share, owing to increasing therapy approvals and launches during the forecast period.
Major factors hampering growth of the market include unfavourable reimbursement policies and manufacturing issues limiting the availability of products at treatment centres.
Major players operating in the market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., PTC Therapeutics, Inc., Orchard Therapeutics Plc., Biomarin Pharmaceutical Inc., Regeneron, Bluebird Bio, Inc. (Celgene Corporation), Freeline Therapeutics Ltd,  MeiraGTx Limited, Kolon TissueGene, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Biogen INC., and Bristol-Myers Squibb Company.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo